RecruitingEarly Phase 1NCT05864170

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia(Child)

Sponsor

Shenzhen Hemogen

Enrollment

3 participants

Start Date

May 27, 2022

Study Type

INTERVENTIONAL

Conditions

Thalassemia

Summary

This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients

Eligibility

Min Age: 18 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called β-globin restored autologous hematopoietic stem cells for people with thalassemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 35 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALβ-globin restored autologous hematopoietic stem cells

β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q

Locations(1)

Shenzhen University General Hospital

Shenzhen, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05864170

Related Trials

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

NCT0439862871 locations

CINC424A2X01B Rollover Protocol

NCT02386800101 locations

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226105 locations

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT057364196 locations

A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

NCT072159752 locations